Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Samantha L Savage, Anna M. Reister Schultz, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Motomi Mori, PhD, Elie Traer, MD PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 2068.

https://doi.org/10.1182/blood.V130.Suppl_1.2068.2068

Published: 2017

Journal Articles

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

Samantha L Savage, Julia E. Maxson, PhD, Christopher A. Eide, Chelsea Jenkins, B.S., Melissa L Abel, Anna M. Reister Schultz, Daniel Bottomly, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2017) 130 (Supplement 1): 3930.

https://doi.org/10.1182/blood.V130.Suppl_1.3930.3930

Published: 2017

Journal Articles

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Stephen E Kurtz, PhD, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Andrea Local, PhD, Hongying Zhang, MD, Stephen Howell, MD, William Rice, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 4626.

https://doi.org/10.1182/blood.V130.Suppl_1.4626.4626

Published: 2017

Journal Articles

Coexisting Oncogenic Signaling Pathway Mutations in Cnl/Acml/CMML/MPN-U

Haijiao Zhang, Daniel Bottomly, Libbey K. White, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 4213.

https://doi.org/10.1182/blood.V130.Suppl_1.4213.4213

Published: 2017

Journal Articles

Definition of the Minimal Truncated Elements Necessary for CSF3R Leukemogenic Potential

Haijiao Zhang, MD, Anna Reister Schultz, B.S., Samuel B Luty, BS, Sophie Means, B.S., Larry David, PhD, John Klimek, B.S., Daniel Bottomly, Beth Wilmot, Shannon McWeeney, PhD, Yulong Su, B.S., Jeffrey W. Tyner

Blood (2016) 128 (22): 2735.

https://doi.org/10.1182/blood.V128.22.2735.2735

Published: 2016

Journal Articles

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

Julia E Maxson, PhD, Jason Gotlib, Angela G. Fleischman, MD, PhD, Christopher A. Eide, Daniel Bottomly, MS, Beth Wilmot, PhD, MS, Shannon McWeeney, PhD, Cristina Tognon, PhD, Marc M Loriaux, MD, PhD, Brian J. Druker, Jeffrey W Tyner, PhD

Blood (2012) 120 (21): 2412.

https://doi.org/10.1182/blood.V120.21.2412.2412

Published: 2012

Journal Articles

Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).

Grover C. Bagby, MD, Shannon McWeeney, PhD, Jane Yates, Byung Park, PhD, R. Keaney Rathbun, Daniela Pilonetto, PhD, Richard Harris, MD, John Wagner, MD, Christina Harrington, PhD, Motomi Mori, PhD, Ricardo Pasquini, MD, D. Wade Clapp, MD

Blood (2006) 108 (11): 2636.

https://doi.org/10.1182/blood.V108.11.2636.2636

Published: 2006

Journal Articles

Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL).

Robert C. Trueworthy, MD, Linda Stork, MD, Yanping Zhong, MD, Sharon Pine, PhD, Yousif Matloub, MD, Ted Laderas, MS, Shannon McWeeney, PhD, Guang Fan, MD, PhD

Blood (2006) 108 (11): 1834.

https://doi.org/10.1182/blood.V108.11.1834.1834

Published: 2006

Journal Articles

Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment.

Michael W. Deininger, MD, PhD, Stephanie Willis, Thoralf Lange, MD, Shannon McWeeney, PhD, Sandra Otto, Brian J. Druker, MD

Blood (2004) 104 (11): 273.

https://doi.org/10.1182/blood.V104.11.273.273

Published: 2004

Journal Articles

Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.

Grover Bagby, MD, Jane Yates, Shannon McWeeney, PhD, Byung Park, MS, Keaney Rathbun, Daniela Pilonetto, PhD, Richard Harris, MD, John Wagner, MD, Gerard Pals, PhD, See Yan Lau, MS, Christina Harrington, PhD, Motomi Mori, PhD, Ricardo Pasquini, MD

Blood (2004) 104 (11): 3416.

https://doi.org/10.1182/blood.V104.11.3416.3416

Published: 2004

NARROW

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Coexisting Oncogenic Signaling Pathway Mutations in Cnl/Acml/CMML/MPN-U

Definition of the Minimal Truncated Elements Necessary for CSF3R Leukemogenic Potential

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).

Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL).

Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment.

Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only